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The acute effects of OPC-8212, a newly synthesized or-
ally effective inotropic agent, were assessed clinically.
Eleven patients with moderate congestive heart failure
received a single mean dose of 6.5 mg/kg body weight
of the drug. Eight hours after administration, the car-
diac and stroke work indexes increased by 11% (p <
0.01) and 20% (p < 0.005), respectively, with concom-
itant decreases in the diastolic pulmonary artery (25%,
p < 0.005) and right atrial pressures (33%, p < 0.01).
There were no signiflcant changes in blood pressure or
heart rate.
The contractile state of the left ventricle was also
The medical treatment of congestive heart failure has, in
addition to administration of diuretic drugs, traditionally
relied on the cardiac glycosides, but these agents have only
a modest effect and a narrow therapeutic index (I). Safer
and more effective inotropic agents have thus been inten-
sively searched for. Synthetic catecholamines such as do-
pamine and dobutamine were the first compounds developed
for this purpose. However, their clinical use is considerably
limited in long-term treatment because they are effective
only with parenteral administration and can cause serious
tachycardia or arrhythmias. Recently, several potent, non-
toxic, orally effective inotropic agents advocated for use in
chronic heart failure have been introduced (2-5). One of
these drugs is 3,4-dihydro-6-(4-(3 ,4-dimethoxybenzoil)-l-
piperazinyl)-2( IH)-quinolinone (OPC-8212), synthesized
quite recently by Tominaga et al. (6). In animal experiments
(7-11) using isolated muscle strips or whole heart prepa-
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assessed by the shift of the Starling curve. To construct
the function curve, lower body negative pressure was
used to regulate the venous return to the heart. An ino-
tropic effect of the agent was confirmed by the stIift of
this function curve upward and to the left, even when
an augmentation of the cardiac output was masked by
the marked reduction in preload. The hemodynamic and
clinical effects of OPC-8212 were encouraging and the
drug appears to be promising for the treatment of
congestive heart failure.
(J Am Coli CardioI1987;9:865-71)
rations this agent produced substantial enhancement of con-
tractility.
Clinical experience with OPC-8212 is limited. However,
a preliminary study (12) demonstrated that peak hemody-
namic effects were observed 8 hours after oral ingestion,
when there was a consistent decrease in diastolic pulmonary
artery pressure. An increase in cardiac output was not clearly
seen in some cases, although the changes in the group data
were statistically significant. In these circumstances, the
concept of the ventricular function curve seems useful in
evaluating load or contractility changes. In the present study,
we evaluated the effects of the acute oral administration of
OPC-8212 within the two-dimensional framework of ven-
tricular function.
Methods
Study patients. We evaluated the acute hemodynamic
effect of oral OPC-8212 in II patients with congestive heart
failure aged 22 to 80 years (mean 55) (Table I). Chest
radiography showed cardiomegaly (cardiothoracic ratio
>50%) in all patients. The causes of heart failure were
cardiomyopathy in five patients (dilated in three, secondary
to myocarditis in two), old myocardial infarction in five and
hypertensive heart disease in one. We included the last
patient in the study group because myocardial pumping abil-
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Table I. Clini cal Characteri st ics of the Stud y Patient s
Age(yf} NYHA EF Total Dose
Case &Sex Diagnosis Class (%) (rug/kg)
22M Dilatedcardiomyopathy II 25 7.4
2 39F Dilated cardiomyopathy IV 31 7.1
3 80F Dilated cardiomyopathy tv 20 6. 1
4 17M Myocarditis IV 19* 5.7
5 40M Myocarditis IV 28 5.9
6 74M Hypertensive heart disease III 44* 6.2
7 68M Old myocardial infarction II 57 6.4
8 60M Old myocardial infarction III 23 6.6
9 53M Old myocardial infarction II 58 6.2
10 45M Old myocardial infarction II 40 6.2
II 45M Old myocardial infarction II 52 7.2
*Obtained by two-dimensional echocardiography. EF = left ventricular ejection fraction: F = female:
M = male; NYHA class = New York Heart Association functional class.
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ity was apparently depressed with dilation of the left ven-
tricular cavity and the patient was not regarded as having
predominant diastolic dysfunction (13). All patients had
normal sinus rhythm and impairmentof ventricularejection.
The rest ejection fraction obtained by radionuclide angi-
ography (in nine patients) or by two-dimensional echocardi-
ography (in two patients) ranged from 19 to 58% (mean
36.1%). Five patients were in New York Heart Association
functional class II, two were in class III and four in class
IV. Digitalis glycosides and other inotropic agents had not
been used by any patient before the study and all other
medications were withheld for 24 hours under close obser-
vation. Informed consent and ethical approval wereobtained
from all patients.
Hemodynamic measurements. A 7F triple lumen ther-
modilution Swan-Ganz catheter was introduced through the
internal jugular vein. Pulmonary artery and right atrial pres-
sures were measured using a Statham P-50 transducer and
were recorded on a forced ink multichannel recorder (Min-
gograph). Cardiac output was measured in triplicate by the
thermodilution technique using a bedside computer (Ed-
wards model 9520). Systemic arterial pressure was mea-
sured directly using an indwelling catheter introduced per-
cutaneously into a brachial artery. The electrocardiogram
was monitored throughout the study.
Venous return was changed by using a negative pressure
chamber on the lower half of the body . Each subject lay
supine on a bed and was enclosed up to the iliac crests in
an airtight box. A vacuum was achieved by use of a standard
vacuum cleaner motor. The level of the vacuum was con-
tinuously measured by a st~ndard mercury manometer linked
to the inside of the box. Right heart pressures. systemic
blood pressure and cardiac output were measured during
baseline conditions and then during the last 90 seconds of
each 4 minute period of lower body negative pressure of
- 20 and - 30 or - 40 mm Hg. Cardiac output was deter-
mined in triplicate. The cardiac function curve was obtained
by relating the diastolic pulmonary artery pressure to the
cardiac or stroke work indexes at each level of lower body
negative pressure.
Aft er control measurements, mean doses of 6.5 mgtkg
body weight (range 5.7 to 7.4) of OPC-8212 were admin-
istered orally . Hemodynamic measurements were repeated
8 hours after administration of the drug. Derived hemo-
dynamic measures were calculated from the standard for-
mulas, SVR = (MAP - RAP) X 80/CO and SWI = SI
x (MAP - DPAP) x 0.0136, where SVR is the systemic
vascular resistance (dynes-s/cm"), MAP, RAP and DPAP
are, respectively, the mean arterial, right atrial and diastolic
pulmonary artery pressures (mm Hg), CO is the cardiac
output (liters/min), SWl is the stroke work index (g-m/rrr')
and Sl is the stroke volume index (ml/beat per rrr').
Statistical analysis. All data are expressed as mean :t
SD, unless otherwise indicated. Hemodynamic changes
produced by OPC-8212 were assessed with a t test for paired
data. A probability (p) value of < 0.05 was accepted as
indicative of statistical significance.
Results
Hemodynamic effects. Hemodynamic measurements at
a lower body negative pressure of 0, - 20 and - 30 or - 40
mm Hg after OPC-8212 are summarized in Table 2. In the
control state without negative pressure, the cardiac index
and stroke index rose from 2.36 ± 0.28 to 2.61 ± 0.35
liters/min per rrr ' (p < 0.01) and from 30.3 ± 6.7 to 33.5
± 5.9 ml/beats per m2 (p < 0.01), respectively. The stroke
work index was also augmented from the baseline value of
30.9 ± 8.9 to 36.8 ± 9.9 g-m/rrr' (p < 0.005). These
moderate increases in ventricular ejection measures were
associated with significant falls in both systolic and diastolic
pulmonary arterial pressures (35.6 ± 17.2 to 28.2 ± 13.8
mm Hg [p < 0.01) and 16.3 :t 8. 1 to 11.8 ± 5.4 mm Hg
[p < 0.05], respectively) . The mean right atrial pressure
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Table 2. Lower Body Negative Pressure-Induced Hemodynamic Changes in \ \ Patients From
Control to S Hours After Single Oral Admi nistration of OPC-S2l2
Lo wer Body Negative Pressure (rnrn Hg)
867
o -20 -30/ -40
CI (liters/min per m:)
C 2.36 ::': 0.28J t 2. 12 :!:: 0.26] 2.00 :!:: 0.25',
0 2.6 1 ::': 0.35 2.2<) :!:: (U I" 2.11 ± 0.23'
SI (ml/beat per m:)
C 30.3 :!:: 0.7J t 26.5 ± 5.2'] t 24.5 :!:: 4.4"
0 33.5 ± 5.<) 29.0 ± 6. 1" 26.0 :!: 3.9'
SWI (gm/nr')
C 30.<J ± 8.9J :j: 28.0 :!: 8.0"J ' 25.9 ± 6.7']
•0 36.8 :!: <J .<) 31.3 :!: <J.8" 28.9 ± 7.5"
HR (beats/min)
C 805 :!: 15.9 81.<) ± 13.0 83.2 :!: 13.0
0 79.0 ± 10.<J 80.5 ± 11 .2 82.0 ± <J .2
SAP (rnm Hg)
C 130.0 ± 20.8 131.6 ± 28.8 127.1 ± 27.1"
0 134.7 ± 35.2 121n ± 32. 1" 130.9 ± 34.9
DAP (mm Hg)
C 7 1.9 :!: 11.0 71.6 :!:: 11.5 72.3 :!:: 12.3
0 71.X :!:: 12.2 68.6 ± 10.0 71.3 :!:: 11.9
MAP (111m Hg)
C 9 1.5 ± 15. l 9 1.6 ± 16 .\ 90.6 ± 16. 1
0 92.8 ± 19.0 8X.5 ± 16.6" 9 1.1 ± IX.X
SPAP (rnrn Hg)
C 35.6 ± 17.2J t 29.8 ± 14.<)" . 27.4 ± 13.4"
0 2li.2 ± 13.8 22.<) ± 10.1" 22.8 ± lOS
DPAP (rnm Hg)
C 16.3 ± 8. IJ 13.6 :!:: 7.W] 12.2 ± 7.3'
0 11.8 :!: 5.4 * 9.5 ± 4.5" * 8.8 ± 4.6'
RAP (m) (rnm Hg)
C 10.8 :!: 6.3J * 8.8 ± 6.7"J 7.5 ± 5.W
*0 6.3 :!: 2.5 4.2 ± 2. 1' 3.5 ± 2.4'
SVR (dynes-s/cnr')
C 1753 :!:: 336 1<)9<J ± 452" 2146 ± 546"
0 1718 :!:: 436 1909 ± 467" 2148 ± 564"
*p < 0.05; t p < (UlI ; :j: p < 0.005 "p < 0.05 versus 0 mm Hg: 0p < 0.01 versus 0 mrn Hg: ' p < 0.005
versus 0 mrn Hg. All values are mean ± SD. C ~ control; CI ~ cardiac index; DAP ~ diastolic arterial
pressure; DPAP ~ diastolic pulmonary artery pressure; HR ~ heart rate; MAP = mean arterial pressure;
o ~ oral administration ofOPC-X2 12; RAP (m) = mean right atrial pressure; SAP = systolic arterial pressure;
SI = stroke index; SPAP = systolic pulmonary artery pressure; SVR ~ systemic vascular resistance:
SWI ~ stroke work index.
was also elevated initially (10.8 ± 6.3 rnrn Hg) and was
markedly reduced after OPC-82l2 (6.3 ± 2.5 rnm Hg, p
< 0.05). Heart rate remained unchanged throughout the
study. There were no significant changes in systemic arterial
pressure and systemic vascular resistance.
Effect on cardiac function curve. Though the mean
cardiac index increased significantly in conjunction with the
reduction in the mean diastolic pulmonary artery pressure,
there was an apparent interpatient variation in response and
three patients showed little change in cardiac index despite
a marked drop in filling pressure (Fig. I). To determine
whether these changes were due to mechanical effects or a
substantial change in contractility, we constructed a left
ventricular function curve by plotting the corresponding car-
diac index and diastolic pulmonary artery pressure relation
at different levels of venous pooling produced by lower body
negative pressure. Moderate ( - 20 rnrn Hg) and maximal
( - 30 or - 40 mm Hg) negative pressure lowered diastolic
pulmonary artery pressure by 17% (p < 0.(05) and 25%
(p < 0.005), respectively, and decreased the cardiac index
by 10% (p < 0.(05) and 15% (p < 0.(05) , respectively,
and the stroke work index by 9% (p < 0.05) and 16% (p
< 0.0 I), respectively, from the baseline state (Table 2).
The same procedure repeated 8 hours after OPC-8212 also
caused a reduction in diastolic pulmonary artery pressure
(19% [p < 0.01] and 25% lp < 0.0051) associated with a
concomitant decrease in ejection index (cardiac index de-
creased by an average of 12% [p < 0.0\] and 19% [p <
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of diastolic pulmonary artery pressure , the cardiac function
curve with OPC- 8212 was clearly shifted to the left of the
control curve before the drug. demonstrating an enhanced
inotropic state (Fig. 3).
Figure 3. Ventricular function curves obtained from the relation
between diastolic pulmonary artery pressure and cardiac index
measuredat each level of lower body negative pressure in the three
patients shown in Figure I who did not exhibit a significant change
in cardiac index. In each case, the curve shifted clearly to the left
after OPC-8212. Symbols and abbreviations as in Figure 2.
30o~L---__"J"...._---~---___+.,...._--___:'o 20
DPAP (mmHg)
Figure l. Relation between diastolic pulmonary artery pressure
WPAP) and cardiac index (CI) in II patients before and after
administration of OPC-82l 2. All data are shown at the control
baseline state and at 8 hours after oral OPC-8212 (arrowhead) .
Though the mean cardiac index increased significantly in con-
junction with the reduction in mean diastolic pulmonary artery
pressure. indicating a shift of the left ventricular function curve
upward and to the left. there were three patients (Patients 2. 3 and
9) who showed little change in the cardiac index despite a marked
drop in the fi lling pressure. The numbers indicate each patient.
0 .005 1and stroke work index by 15% [p < O.OIJ and 2 1%
[p < 0 .0 11, respect ively, at moderate and maximal levels
of lower body negati ve pressure). Heart rate remained un-
changed at any level of lower body negative press ure both
before and after administration of OPC-82 12.
Cardiac function with OPC-8212 was augmented as re-
flected by a left and upward shift of the cardiac function
curve (Fig. 2) . Even in the three patients who showed little
change in the cardiac index (less than 10%) with a reduction
Discussion
Effect of OPC-8212 in cardiac performance. Cardiac
performan ce can be influenced by two mechani cal factors,
rest fiber length (preload) and forces resisting ejection (af-
terload). Each of these will affec t muscle shorte ning inde-
pendently if one of the factors and the existing inotrop ic
state are held constant. With depressed myocardial con-
tractility , the normal cardiac output is maintained if the
ventricle can utilize the preload reserve with simultaneous
enhancement of venous return ( 14. 15). Because cardiac out-
Figure 2. Relation between mean
values of diastolic pulmonary artery
pressure (DPAP)and cardiac index (CI)
(A) or stroke work index (SWI) (8)
before (open symbols) and after
administration of OPC-821 2 (closed
symbols) during lower body negative
pressure. Diastolic pulmonary artery
pressure decreased significantly in
conjunction with a significant aug-
mentation of the cardiac and stroke
work indexes in the basal rest state
after OPC-8212. The left ventricle
clearlyshiftedtoa new functioncurve.
which was displaced to the left with a
steeper slope by the positive inotropic
effect of the drug. The circles repre-
sent a lower body negative pressure of
omm Hg: the triangles - 20 mm Hg:
and the squares - 30or - 40 mm Hg.
All values are mean ± SEM.
1'0 is 20
DPAP (mmHg)
40 B
20io is
DPAP (mmHg)
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put is dependent on peripheral factors, an augmentation of
myocardial contractility does not necessarily elevate cardiac
output if there is a simultaneous reduction in preload. There-
fore under these circumstances, a single measurement of
shortening characteristics in the rest state is not sufficient
for defining the basal inotropic state (16).
In the present study, 8 hours after oral administration of
OPC-8212 a substantial fall was observed in filling pressure
in all cases; however, this reduction was associated with a
small change in cardiac index in three patients. Thus, the
concept of a two-dimensional framework that takes into
account the rest fiber length of the ventricle and its pumping
capability is convenient to understand the composite hemo-
dynamic picture of the entire circulation. The analysis of
changes in relative positionof the functioncurve constructed
by relating cardiac index to an index of preload allowed us
to identify whether the leftward shift of this single point
signified that the ventricle was moving down along a single
relation, or whether it represented a displacement of the
entire curve to the left.
Cardiac function curve during lower body negative
pressure. Ross et al. (17) reduced the ventricular filling
pressure by impeding venous return to the heart by pro-
gressively inflating a balloon in the inferior vena cava. and
determined the relation between the left ventricular end-
diastolic or filling pressure and stroke volume. This method
was shown to provide a useful framework for considering
the directional responses of the human ventricle to various
forms of stress. In the present study, we applied lower body
negative pressure to regulate venous return. This maneuver
produces orthostatic stress independent of gravity by ele-
vation of the lower body vascular transmural pressure (18).
It provides a reproducible and effective means of depleting
the effective blood volume and reducing central venous
pressure, and hence preload to the ejecting ventricle.
The ad vantages o] this method are that I) the procedure
is noninvasive, 2) the stress can be quantified and controlled
by the amount of pressure applied, and 3) pooled blood can
be replaced as desired. The blood volume pooled during a
negative pressure of - 30 to - 50 rnrn Hg is approximately
0.5 to 1.0 liter. The central venous pressure falls by 3 to 7
rnm Hg during application of lower body negative pressure
in the range of - 10 to - 60 mm Hg (18). It also has been
reported (1 9- 21 ) that a negative pressure of - 30 to - 60
mrn Hg in normal subjects is accompanied by reduction in
stroke volume of 20% to 50%.
Limitations of study. Certain limitations of the present
method should be given attention. Though ventricular end-
diastolic pressure is analogous to the preload of isolated
muscle and it determines the rest length of sarcorneres in
the ventricular wall within physiologic loads, the relation
between end-diastolic pressure and end-diastolic volume is
nonlinear. Furthermore, this relation is also affected by the
diastolic property of the heart (22). At higher end-diastolic
pressures, end-diastolic pressure rises substantially without
significant increments in diastolic volume. In the present
study. tilling pressures attained at the maximal negative
pressure were well below 20 mm Hg (averaging 12.2 ±
7.3 mm Hg in the control period and 8.8 ± 4.6 mm Hg
after OPC-821 2), a level at which the ventricle is assumed
to be operating on the ascending limb of the Frank-Starling
curve (23).
Venous pooling produced by lower body negative pres-
sure in awake humans is accompanied by baroreflex re-
sponses and affects the inotropic state. Zoller et aJ. (24)
reported that during a negative pressure of - 5 to - 10 mm
Hg, the forearm blood flow and central venous pressure
decreased without significant changes in the systolic blood
pressure and heart rate. This response was associated with
an activation of low pressure baroreceptors, a situation in
which the inotropic state is considered not to be affected.
On the other hand. during a high negative pressure (- 40
mm Hg), the decrease in forearm blood flow and central
venous pressure was accompanied by a signifi cant reduction
in systolic blood pressure and a signifi cant increase in heart
rate by reflexes mediated by the high pressure baroreceptors.
In these circumstances, the inotropic state might not remain
unchanged. However, in our present study, heart rate did
not appreciably change at any level of negative pressure.
This lack of the effect on heart rate provided evidence that
the inotropic state of the ventricle remained constant during
lower body negative pressure at the levels employed in the
present study. The cardiac function curve constructed with
this maneuver consistently shifted upward and to the left
after the administration of OPC-8212, clearly indicating a
positive inotropic effect.
Mechanisms for the impairment of reflex-mediated
tachycardia during graded levels of negative pressure.
These mechanisms have remained unclear. There have been
several studies (25-27) concerning the abnormal responses
of heart rate to postural change or negative pressure in
patients with congestive heart failure. The following pos-
sible mechanisms could be considered. First, lower body
negative pressure could fail to produce an adequate stimulus
for reflex-mediated tachycardia, because the veins are less
distensible in patients with heart failure than in normal sub-
jects (28). However, an apparent fall of right atrial and
pulmonary pressures and cardiac index precludes the pos-
sibility that a lack of change in heart rate during the pro-
cedure can be entirely accounted for by the lack of change
in cardiac fill ing. Second, heart failure alters the barore-
ceptor-mediated control of the systemic circulation
(25-27,29-3 1). In animals and humans with moderately
severe ventricular dysfunction, baroreflex-rnediated cardiac
slowing induced by a rise in arterial pressure with phenyl-
ephrine was markedly inhibited (29,30). Ferguson et al.
(25) reported that in patients with class II to IV congestive
heart failure, lower body negative pressure at - 10and - 40
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mm Hg produced no significant changes in heart rate; this
is compatible with our results. In these patients, such im-
pairment of baroreflex control was immediately normalized
by administration of a digitalis glycoside, possibly because
of baroreceptor sensitization. Furthermore, other investi-
gators (26,27) have shown that a reflex increase in plasma
norepinephrine on tilt was absent in patients with congestive
heart failure. Such defective humoral control might also be
responsible for the lack of heart rate response to negative
pressure. Third, previous studies (32,33) offer evidence fa-
voring beta-adrenergic receptor dysfunction in failing hearts.
Bristow et al. (32) reported that the failing left ventricle
obtained from patients undergoing cardiac transplantation
had a 50 to 56% reduction in beta-adrenergic receptor den-
sity. This reduction may result in decreased responsiveness
to beta-receptor stimulation in patients with heart failure
(33 ).
Mechanisms of the hemodynamic effect ofOPC-8212.
These are not known. There are no similarities in the chem-
ical structure of this agent to that of glycosides, catechol-
amines or other inotropic agents (34). Because the response
of the drug was not blocked by a beta-adrenoceptor antag-
onist, its positive inotropic effect has been assumed not to
be mediated through a beta-adrenoceptor mechanism (7,8).
It is of particular interest that the cardiotonic action of OPC-
8212 is enhanced in heart preparations that have been de-
pressed by prior administration of pentobarbital (7), pro-
pranolol (8) or a calcium channel blocker (II). The inotropic
effect of OPC-8212 is apparent even in the presence of
ouabain, which suggests that the mechanism of action of
this agent is different from that of digitalis (II). This agent
does not inhibit sodium-potassium (Na-K) adenosine tri-
phosphatase of canine cardiac muscle (7). It has been shown
that the inotropic effect of OPC-8212 is likely to be mediated
by an increase in the intracellular calcium ion concentration.
Endo (35) reported that OPC-82l2 does not directly affect
the calcium uptake and calcium release activity of the sar-
coplasmic reticulum of fibers of the guinea pig ventricle.
OPC-8212 produces an increase in the plateau and overshoot
potentials of the action potential and its duration in depo-
larized cardiac cells (7,36,37). These findings suggest that
the drug increases the magnitude of the slow inward calcium
current in ventricular muscle fibers, which has been regarded
as a fundamental mechanism for the positive inotropic ef-
fects of OPC-82l2 (7,36).
The increase in force of contraction with OPC-82l2 was
shown to be associated with a parallel increase in intracel-
lular concentrations of cyclic adenosine monophosphate as
a result of the inhibition of phosphodiesterase (7). However,
the inhibition of phosphodiestrase may not be the major
action of OPC-82l2 because this agent does not exert any
positi ve chronotropic effect. OPC-8212 may have a novel
mechanism of action other than phosphodiesterase inhibi-
tion.
Conclusions. OPC-8212 clearly improved rest hemo-
dynamics. Augmented contractility of the heart after admin-
istration of the drug was demonstrated by a leftward and
upward shift of the cardiac function curve constructed by
alteration of loading conditions. The positive inotropic ef-
fect of this agent is relatively mild and the drug may be
particularly useful for the treatment of mild to moderate
cardiac failure in which pumping ability is relatively main-
tained at rest but is considerably limited during stress. No
adverse effects were observed during the study. The im-
provement in cardiac function was not accompanied by a
significant change in heart rate. Further investigation is war-
ranted to determine its eventual place in the treatment of
congestive heart failure.
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